samedan logo
 
 
 
spacer
home > ebr > summer 2020 > would greater diversity and inclusion improve innovation?
PUBLICATIONS
European Biopharmaceutical Review

Would Greater Diversity and Inclusion Improve Innovation?

We have seen just how important the pharmaceuticals industry is to the global economy and society in recent weeks. The collaboration over the COVID-19 pandemic is an example of the industry at its best. Pharma executives are clearly committed to bringing drugs to market to improve the lives of patients, but the big question is whether the industry is too introspective to be truly innovative?

When the pharma industry lacks diversity within, it underserves patients outside. This is not simply a moral problem, it is a practical one too. A lack of diversity in decision-making leads to lack of insight that could otherwise contribute to improving and saving lives. While the industry is certainly diverse, in terms of nationality and culture at least, there’s no doubt it could be more inclusive.

Part of pharma’s problem is insularity in hiring practices and an over-confidence in its own abilities. Can the industry really meet diverse, new patient and customer needs if it is yet to fully embrace inclusion among its own staff base?

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Stephen Frost is the founder of global diversity and inclusion consultancy Frost Included and co-author of new book Building An Inclusive Organization, published by Kogan Page.
spacer
Stephen Frost
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma enters into Development and Manufacturing Agreement with Synklino

Vilnius, Lithuania, and Copenhagen, Denmark – December 18th 2019 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Synklino, a company active in developing a therapeutic protein based therapy as treatment for cytomegalovirus (CMV) infection, announced today that they entered into a Development and Manufacturing Agreement for the recombinant fusion protein SYNx, which Synklino aims to bring into clinical trials.
More info >>

White Papers
 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement